Ohio is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program
NCT04632953
Recruiting
The primary objective of this study is to assess the long-term safety, including pregnancy, infant, and lactation outcomes, of patients with LC-FAOD who are enrolled in the DMP.
Gender:
ALL
Ages:
All
Trial Updated:
07/18/2025
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Register for Updates
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
NCT04333576
Recruiting
Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relationships, sexuality and sexual activity, and mental health. This study will evaluate how well elagolix in combination with combined oral contraceptives (COC) works within the body and/or how safe it is compared to placebo (does not contain treatment drug). This study will assess the dysmenorrhea (painful periods) response in participants with endomet... Read More
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
07/18/2025
Locations: Clinical Inquest Center Ltd /ID# 217961, Beavercreek, Ohio
Conditions: Endometriosis
Register for Updates
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
NCT03313778
Recruiting
The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: The Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Solid Tumors
Register for Updates
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226
Recruiting
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/17/2025
Locations: Optima Research, Boardman, Ohio
Conditions: Plaque Psoriasis
Register for Updates
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
NCT06921759
Recruiting
The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/17/2025
Locations: Optima Research - Boardman, Boardman, Ohio
Conditions: Atopic Hand and Foot Dermatitis
Register for Updates
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Care Access - Lima, Lima, Ohio
Conditions: Type 1 Diabetes, Obesity, Overweight
Register for Updates
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
NCT06864026
Recruiting
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Paramount Medical Research & Consulting, LLC, Middleburg Heights, Ohio
Conditions: Psoriatic Arthritis, Overweight or Obesity
Register for Updates
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
NCT06857942
Recruiting
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Optima Research - Boardman, Boardman, Ohio
Conditions: Psoriasis, Overweight or Obesity
Register for Updates
Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
NCT06857240
Recruiting
This study will assess the safety and efficacy of topical ruxolitinib for treating the refractory cutaneous manifestations in patients with dermatomyositis. The investigators' hypothesis is that topical ruxolitinib will be both safe and effective for such patients.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
07/17/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Dermatomyositis
Register for Updates
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)
NCT06852222
Recruiting
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukemia (AML).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Gabrail Cancer Center, Canton, Ohio
Conditions: Leukemia, Myeloid, Acute
Register for Updates
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
NCT06785012
Recruiting
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
07/17/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Depressive Disorder, Major
Register for Updates
ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty
NCT06753916
Recruiting
The main objective of this study is to determine the safety of Ex Vivo Cross Linking (CXL) of donor corneal tissue in participants who have undergone high-risk penetrating keratoplasty.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Cincinnati Eye Institute, Cincinnati, Ohio
Conditions: Corneal Transplant Failure
Register for Updates